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Abstract: Background: Uropathogenic Escherichia coli (UPEC) has increased the incidence of urinary
tract infection (UTI). It is the cause of more than 80% of community-acquired cystitis cases and
more than 70% of uncomplicated acute pyelonephritis cases. Aim: The present study describes the
molecular epidemiology of UPEC O25b clinical strains based on their resistance profiles, virulence
genes, and genetic diversity. Methods: Resistance profiles were identified using the Kirby–Bauer
method, including the phenotypic production of extended-spectrum β-lactamases (ESBLs) and
metallo-β-lactamases (MBLs). The UPEC serogroups, phylogenetic groups, virulence genes, and
integrons were determined via multiplex PCR. Genetic diversity was established using pulsed-
field gel electrophoresis (PFGE), and sequence type (ST) was determined via multilocus sequence
typing (MLST). Results: UPEC strains (n = 126) from hospitalized children with complicated UTIs
(cUTIs) were identified as O25b, of which 41.27% were multidrug resistant (MDR) and 15.87% were
extensively drug resistant (XDR). The O25b strains harbored the fimH (95.23%), csgA (91.26%), papGII
(80.95%), chuA (95.23%), iutD (88.09%), satA (84.92%), and intl1 (47.61%) genes. Moreover, 64.28%
were producers of ESBLs and had high genetic diversity. ST131 (63.63%) was associated primarily
with phylogenetic group B2, and ST69 (100%) was associated primarily with phylogenetic group D.
Conclusion: UPEC O25b/ST131 harbors a wide genetic diversity of virulence and resistance genes,
which contribute to cUTIs in pediatrics.
Keywords: UPEC O25; MDR; MLST; genetic diversity
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1. Introduction
Urinary tract infections (UTIs) are a public health problem in Mexico and the second
leading cause of morbidity worldwide. UTIs are the main infections associated with
prolonged hospital stay. The use of medical devices, such as urinary catheters, has increased
the incidence of UTIs of hospital origin, which are primarily associated with uropathogenic
Escherichia coli, commonly called UPEC [1].
UPEC is the causative agent of more than 80% of community-acquired cystitis, more
than 70% of uncomplicated acute pyelonephritis, and 3.6–12.6% of complicated UTIs
(cUTIs) with urosepsis [2]. Serological typing using serogroup O (lipopolysaccharide)
has made it possible to identify clinical strains of UPEC with well-identified virulence
factors [3]. Clinical strains of UPEC are primarily related to serogroups O1, O2, O4, O6, O7,
O8, O15, O16, O18, O21, O22, O25, O75, and O83 [3]. Clinical strains of UPEC belonging to
serogroup O25 (UPEC O25) have been reported in various populations, including adult
patients hospitalized with symptomatic UTIs [4], adult patients with community-associated
UTIs [5,6], female patients prone to acute cystitis [7], and children with UTIs [8].
Clinical strains of UPEC O25 are related to a high presence of virulence factors, such
as fimbrial adhesins (FimH, PapG, and SfA); toxins such as cytotoxic necrotizing fac-
tor 1 (CNF1), α-hemolysin (HlyA), and enterotoxin (Set1); iron scavengers (IronN); and
siderophores (Iuc and FyuA) [4,5]. UPEC O25 clinical strains have a multidrug-resistant
(MDR) profile for various antibiotics and produce extended-spectrum β-lactamases (ES-
BLs) [9].
Phylogenetic tools for the identification of clonal complexes (CCs) and sequence types
(STs) differentiate UPEC strains based on their pathogenic and commensal origins. CC73,
CC69, and CC141 were associated with UPEC strains recovered from patients with UTIs,
and the CC10 and CC95 complexes were found primarily among commensal strains of
the normal intestinal microbiota of healthy individuals [10]. However, the identification
of CCs in pathogenic and commensal strains from healthy individuals is indicative of
cross contamination during the establishment of UTIs [10]. Several STs (ST69, ST10, ST131,
and ST648) were identified in extraintestinal strains of E. coli. The typification in specific
populations of STs is primarily related to geographic region [11–13]. UPEC O25b clinical
strains from patients with UTIs belonging to ST131 were related to hospital outbreaks, had
a multidrug-resistant (MDR) lineage, and were ESBL producers of the cefotaximase-M
(CTX-M) type, which hydrolyze third-generation cephalosporins (cefotaxime, ceftriaxone,
and ceftazidime) [14].
Clinical strains of MDR and extremely drug-resistant (XDR) UPEC isolated from Mex-
ican children with cUTIs in the Children’s Hospital of Mexico Federico Gomez (HIMFG)
were previously characterized [15,16]. Phylogenetic analyses using pulsed-field gel elec-
trophoresis (PFGE) and enterobacterial repetitive intergenic consensus–polymerase chain
reaction (ERIC-PCR) showed the presence of clades that were closely related to phyloge-
netic groups B2 and D [15,16]. Preliminary data described UPEC strains collected from
pediatric patients of the HIMFG with an MDR profile and a serogroup of O25b [16]. STs
and CCs were related to virulence in clinical strains of UPEC O25b from pediatric patients,
but additional studies are required to elucidate their pathogenesis. In the present study,
we evaluated the resistance profile against 10 antibiotic categories, β-lactamase phenotype
expression [ESBL and Metallo-β-Lactamase (MBL)], integron classes (1 and 2), and fre-
quency of 17 virulence genes to analyze genetic diversity using PFGE (macrorestriction
patterns) and multilocus sequence typing (MLST; STs and CCs) in a set of clinical strains of
serogroup O25b UPEC recovered from children with cUTIs from the HIMFG.
2. Materials and Methods
2.1. Clinical Strains of UPEC
A total of 129 clinical UPEC strains of serotype O25b were included in this study. The
UPEC strains were recovered from pediatric patients with cUTIs who were hospitalized
in different service areas of HIMFG from 2009 to 2018. The clinical UPEC strains were
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phenotypically identified using an automated Vitex® 2 system (BioMérieux, Marcy l’Étoile,
France) and kept at −70 ◦C in brain heart infusion broth (BHI; BD-Difco, Franklin Lakes,
NJ, USA) supplemented with 20% glycerol (Sigma-Aldrich, St. Louis, MO, USA) and 0.5%
fetal bovine serum (ATCC, Manassas, VA, USA).
2.2. Typing of UPEC O25b Clinical Strains
Genomic DNA was extracted using a Quick-DNATM Universal Kit (Zymo Research,
Irvine, CA, USA) and quantified in a NanoDropTM 2000 (Thermo Fisher Scientific, Waltham,
MA, USA). Genomic DNA was electrophoretically separated to verify its integrity and
used for the identification of UPEC strains of serotype O25b by allele-specific double
PCR [17]. Briefly, PCR amplified the 347 bp pabB gene, which is specific for serogroup
O25b/ST131 due to a single-nucleotide polymorphism (SNP) at the 3′ position, and the
427 bp trpA gene, which is a housekeeping gene (tryptophan synthase alpha subunit). The
specific primers and amplification conditions are shown in Table S1. PCR was performed
with MasterMix (Promega, Madison, WI, USA) and 1 µL of DNA (200 ng/µL) in a total
reaction volume of 12.5 µL under the following conditions: denaturation at 95 ◦C for 5 min;
35 cycles of denaturation at 95 ◦C for 1 min, annealing at 65 ◦C for 1 min, and extension at
72 ◦C for 1.5 min; and final extension at 72 ◦C for 5 min. The DNA products were verified
by electrophoresis in 1% agarose gels after staining with 0.5 mg/mL ethidium bromide
(Sigma Aldrich, St. Louis, MO, USA) and visualization under UV light using a ChemiDoc
MP imaging system (Bio-Rad, Hercules, CA, USA). UPEC 42U-0612 O25b was used as a
positive control [16].
2.3. Antimicrobial Susceptibility Profile of UPEC O25b Strains
The susceptibility to antibiotics of the 129 clinical strains of UPEC O25b was de-
termined using the Kirby–Bauer method via diffusion with Sensi-Discs (BD, Franklin
Lakes, NJ, USA) on Mueller-Hinton agar (MHA, BD-Difco, Franklin Lakes, NJ, USA).
Seventeen antibiotics from 10 categories were included in this study: penicillins: ampi-
cillin (AM-10 µg); β-lactam combination agents: amoxicillin–clavulanate (AMC-20/10 µg)
and piperacillin–tazobactam (TZP-100/10 µg); first- and second-generation cephems:
cephalothin (CF-30 µg) and cefaclor (CEC-30 µg); third-generation cephems: cefotaxime
(CTX-30 µg) and ceftazidime (CAZ-30 µg); monobactams: aztreonam (ATM-30 µg); fluoro-
quinolones: levofloxacin (LVX-5 µg), norfloxacin (NOR-10 µg), and ofloxacin (OFX-5 µg);
carbapenems: meropenem (MEM-10 µg) and imipenem (IPM-10 µg); aminoglycosides:
gentamicin (GM-10 µg); folate pathway antagonists: trimethoprim–sulfamethoxazole (SXT-
1.25/23.75 µg); tetracyclines: tetracycline (TE-30 µg); and nitrofurans: nitrofurantoin
(F/M-300 µg). The methodology was performed following the indications of the Clinical
and Laboratory Standards Institute (CLSI) [18] and as described by Ochoa et al. [15]. MDR
strains were defined as strains with acquired nonsusceptibility to at least one antibiotic
in three or more antibiotic categories. XDR strains were defined as strains that were not
susceptible to at least one agent in all but two or fewer antibiotic categories [19].
2.4. Phenotypic Determination of ESBL and MBL Production in Clinical Strains of UPEC O25b
The phenotypic determination of ESBL and MBL production was performed using
sensitivity tests to several antibiotic discs: for ESBLs, CAZ (30 µg), ATM (30 µg), and
CRO (30 µg); and for MBLs, MEM (10 µg) and IPM (10 µg). Phenotypic determinations
were performed as suggested by the CLSI [18]. Double-disc synergy and individual disc
assays were performed as previously described by our working group [15]. The ESBL
phenotype of clinical UPEC strains was also confirmed using Hodge’s test. Klebsiella
pneumoniae ESBLs+ (ATCC 700603), E. coli ESBLs negative (ATCC 25922), Pseudomonas
aeruginosa MBLs− (ATCC 27853), and P. aeruginosa MBLs positive (540UC1) were used as
controls [15,20].
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2.5. Typing of Phylogenetic Groups, Virulence Genes, and Integrons Associated with UPEC
O25b Strains
Phylogenetic groups and subgroup typing for the clinical strain UPEC O25b were
performed as proposed by Clermont et al. [21]. The UPEC 42U-0612 strain belonging to
phylogenetic group B22 was used as a positive control [16].
Seventeen genes associated with UPEC pathogenesis were investigated: three variant
adhesins of the PapG pilus (papGI, papGII, and papGIII), the FimH adhesin of the type 1
fimbria (fimH), the CsgA adhesin of fimbria curli (csgA), the EcpA adhesin of the ECP pilus
(ecpA), cellulose (a surface glycan, bcsA), the IutD Fe-binding siderophore aerobactin (iutD),
yersiniabactin (fyuA), the ChuA heme group scavenger (chuA), the HlyA pore-forming toxin
(hlyA), the TosA RTX protein (tosA), the SatA autotransporter (satA), cytotoxic necrotizing
factor 1 (cnf1), and flagellar proteins [flagellin fliC) and flagellar motor (motA and motB)].
Endpoint and multiplex PCRs were performed in a Veriti 96-well thermal cycler (Applied
Biosystems, Foster City, CA, USA). UPEC CFT-073 and previously reported clinical strains
were included in this study and used as reference controls [15,16]. The class 1 (intl1) and 2
(intl2) integrase genes were amplified using multiplex PCR as described by Ochoa et al. [15].
UPEC clinical strains 502U1-0412 (intl1) and 674U-0612 (intl2) were used as controls [15].
The primers and reaction conditions are shown in Table S1.
2.6. Pulsed-Field Gel Electrophoresis (PFGE) of Clinical UPEC O25b Strains
PFGE tests were performed according to Ochoa et al. [15]. First, the UPEC O25b strains
were embedded in low-melting-point (LMP) agarose blocks from Promega Corporation
(Madison, WI, USA). Next, digestion of the samples was performed using 20 U of the
restriction enzyme Xba1 (New England Biolabs, Ipswich, MA, USA) at 37 ◦C for 20 h. The
PFGE shift was performed for 24 h at 200 V (7 v/cm) to an angle of 120◦ at 14 ◦C, with an
initial pulse of 2.16 s and a final pulse of 13.58 s, in a CHEF Mapper system (Bio-Rad Life
Science Research, Hercules, CA, USA). The macrorestriction products in the PFGE gels were
stained with GelRed® Nucleic Acid Stain (Biotium, Fremont, CA, USA), visualized with
UV light, and digitized using the CCD Camera Documenting System BK04S-3 (Biobase,
Mexico City, Mexico). PFGE pulsotypes were analyzed using NTSYSpc v2.02j and PAST
v4.03 software, and the clonality degree was estimated according to the criteria described
by Tenover et al. [22]. A lambda ladder PFGE marker (New England Biolabs, Hertfordshire,
England, UK) was used as a molecular weight marker in the PFGE assay.
2.7. Typing of UPEC O25b Clinical Strains Using MLST
Identification of the STs of the UPEC O25b clinical strains was performed via the am-
plification of seven housekeeping genes, as suggested by the Escherichia coli MLST website
(https://pubmlst.org/escherichia/; accessed on 13 October 2021) of the University of Ox-
ford and according to the protocols described by Wirth et al. [23] and Jolley et al. [24]. Briefly,
internal fragments of adk (adenylate kinase), fumC (fumarate hydratase), gyrB (DNA gy-
rase), icd (isocitrate/isopropylmalate dehydrogenase), mdh (malate dehydrogenase), purA
(adenylosuccinate dehydrogenase), and recA (ATP/GTP binding motif) were designed, am-
plified (PhusionTM high-fidelity DNA polymerase, (Thermo Fisher Scientific, Waltham, MA,
USA), purified, and sequenced using the Illumina NextSeq600 platform (NGS, Illumina,
Inc., San Diego, CA, USA) on 1 µg of genomic DNA. Multiple sequence alignment was
performed to identify regions with 100% identity. The readings, filtration, assembly, and
mapping were analyzed as described by Mancilla-Rojano et al. [25]. The ST for each allelic
profile was assigned based on the MLST platform at https://pubmlst.org/escherichia/;
accessed on 13 October 2021. The designed primers, their products, and amplification
conditions are shown in Table S1.
2.8. Statistical Analysis
ANOVA with Fisher’s protected least significant difference (PLSD) and StatView
4.5 software for Windows (www.statview.com; accessed on 26 September 2019) [26]
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were used to determine the statistical significance of the data. A p-value of <0.05 was
considered to indicate statistical significance. A heat map associated with the phyloge-
netic groups and virulence genes was generated using GraphPad Prism 8.0.1 software
(https://www.graphpad.com/scientific-sofware/prism/; accessed on 15 November 2020).
PFGE pulsotypes were analyzed with NTSYSpc v2.02j software (Applied Biostatistics, Inc.,
Setauket, NY, USA) using Jaccard’s coefficient of similarity and clustering analysis by the un-
weighted pair group method using arithmetic averages (UPGMA) and PAST v4.03 software
(https://past.en.lo4d.com/windows; accessed on May 30, 2021). The dendrogram was
edited using the iTOL interactive tree of life (https://itol.embl.de/; accessed on 3 June 2021).
The CCs were analyzed with PHYLOViZ software (https://online.phyloviz.net/index;
accessed on 13 September 2021) using the eBURST algorithm [27].
3. Results
3.1. UPEC O25b Strains Associated with cUTIs
A total of 129 clinical strains of UPEC O25b were recovered from patients with cUTIs
who were hospitalized in various service areas of the HIMFG from 2009 to 2018. The clinical
strains of UPEC O25 belonged to ST131-amplified DNA products of length 347 bp and
427 bp, which correspond to the molecular sizes of the pabB and trpA genes, respectively.
3.2. Multidrug Resistance Profile of UPEC O25b Clinical Strains
The antibiotic susceptibility tests revealed that 81.74% (103/126) of the UPEC O25b
strains were classified as (MDR), and 18.25% (23/126) were classified as (XDR). The remain-
ing three UPEC O25b strains that were not classified as MDR or XDR were excluded from
this study. The 126 UPEC O25b MDR and XDR strains showed resistance to penicillins
[AM (99.20%)]; β-lactams combined with inhibitors [TZP (92.85%) and AMC (77.7%)]; first-,
second-, and third-generation cephalosporins [CF (85.71%), CEC (83.33%), CTX (77.77%),
and CAZ (77.77%)]; and fluoroquinolones [LVX (77.77%), NOR (77.77%), and OFX (77.77%)]
(Table 1 and Figure 1). The UPEC O25b strains showed the least resistance to carbapenems
[MEN (7.94%) and IPM (7.94%)] and nitrofurans [F/M (7.94%)] (Table 1 and Figure 1). The
MDR and XDR profiles of the 126 UPEC O25b strains that showed resistance exhibited
the following distribution: 1.58% (2/126) were resistant to three categories of antibiotics
(MDR-3), 11.90% (15/126) were MDR-4, 11.11% (14/126) were MDR-5, 15.87% (20/126)
were MDR-6, and 41.27% (52/126) were MDR-7. A total of 15.87% (20/126) of the UPEC
O25b strains were resistant to eight categories of antibiotics (XDR-8), and 2.38% (3/126)
were XDR-9. The MDR-7 phenotype was the most prevalent among the UPEC O25b strains.
Table 1. Resistance to 10 antibiotic categories and ESBL production of 126 UPEC O25b clinical strains.
Antibiotic
(µg)













AM-10 6 (100) 12 (100) 76 (100) 18 (100) 13 (92.86) 125 (99.20)
β-Lactam/combination agents
AMC-20/10 6 (100) 11 (91.7) 52 (68.42) 15 (83.33) 14 (100) 98 (77.77)
TZP-100/10 6 (100) 12 (100) 70 (92.11) 15 (83.33) 14 (100) 117 (92.85)
Cephems 1st and 2nd
CF-30 6 (100) 12 (100) 71 (93.42) 8 (44.44) 11 (78.57) 108 (85.71)
CEC-30 6 (100) 9 (75) 73 (96.05) 8 (44.44) 9 (64.29) 105 (83.33)
Cephems 3rd
CTX-30 6 (100) 8 (66.7) 72 (94.74) 4 (22.22) 8 (57.14) 98 (77.77)
CAZ-30 6 (100) 8 (66.7) 72 (94.74) 4 (22.22) 8 (57.14) 98 (77.77)

















ATM-30 6 (100) 7 (58.33) 68 (89.47) 5 (27.78) 6 (42.86) 92 (73.01)
Carbapenems
MEM-10 0 (0) 2 (16.7) 1 (1.31) 2(11.11) 5 (35.71) 10 (7.94)
IPM-10 0 (0) 2 (16.7) 1 (1.31) 2 (11.11) 5 (35.71) 10 (7.94)
Aminoglycosides
GM-10 4 (66.7) 5 (41.7) 42 (55.26) 11 (61.11) 7 (50) 69 (54.76)
Tetracyclines
TE-30 6 (100) 10 (83.33) 65 (85.52) 15 (83.33) 11 (78.57) 107 (84.92)
Fluoroquinolones
LVX-5 6 (100) 6 (50) 73 (96.05) 6 (33.33) 7 (50) 98 (77.77)
NOR-10 6 (100) 6 (50) 73 (96.05) 6 (33.33) 7 (50) 98 (77.77)
OFX-5 6 (100) 6 (50) 73 (96.05) 6 (33.33) 7 (50) 98 (77.77)
Folate pathway antagonists
SXT-1.25/23.75 3 (50) 3 (25) 44 (57.87) 13 (72.22) 7 (50) 70 (55.55)
Nitrofurans
F/M-300 2 (33.3) 1 (8.33) 4 (5.26) 1 (5.56) 2 (14.29) 10 (7.94)
ESBLs
5 (83.33) 8 (66.66) * 59 (77.63) ˆ + 3 (16.66) *ˆ 6 (42.85) + 81 (64.28)
Integrons
Int-1 (intl1) 4 (66.66) 2 (16.66) ◦∞ 37 (48.68) ◦ 10 (55.55) ∞ 7 (50.00) 60 (47.61)
Int-2 (intl2) 1 (16.66) 1 (8.33) 2 (2.63) 0 (0.00) 0 (0.00) 4 (3.17)
AM-10 (ampicillin), AMC-20/10 (amoxicillin–clavulanate), TZP-100/10 (piperacillin–tazobactam), CF-30 (cefalotin), CEC-30 (cefaclor),
CTX-30 (cefotaxime), CAZ-30 (ceftazidime), ATM-30 (aztreonam), MEM-10 (meropenem), IPM-10 (imipenem), GM-10 (gentamicin), TE-30
(tetracycline). LVX-5 (levofloxacin), NOR-10 (norfloxacin), OFX-5 (ofloxacin), SXT-1.25/23.75 (trimethoprim–sulfamethoxazole), F/M-300
(nitrofurantoin), TR (total resistance), Int-1 (integrase class 1), Int-2 (integrase class 2), and 1st, 2nd and 3rd (generation of cephems).
Statistically significant: * p = 0.0024; ˆ p < 0.0001; + p = 0.0066; ◦ p = 0.0404, and ∞ p = 0.0380.
Figure 1. Heat map of virulence genes and antibiotic resistance profiles associated with UPEC O25b
strains. Clinical strains of UPEC showing five phylogenetic subgroups: 17 virulence genes (fimH,
csgA, ecpA, papGI, papGII, papGIII, fliC, motA, motB, iutD, fyuA, chuA, bcsA, cnf1, hlyA, tosA, and satA),
17 resistance profiles (AM, AMC, TZP, CF, CEC, CTX, CAZ, ATM, MEM, IPM, GM, TE, LVX, NOR,
OFX, SXT, and F/M), and ESBL phenotype.
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3.3. Resistance Associated with the Phenotypic Expression of ESBLs and Integrons
ESBL phenotypic expression was determined for the 126 UPEC O25b strains as sug-
gested by CLSI [18]. Briefly, 64.28% (81/126) of the UPEC O25b strains were ESBL producers
according to the synergism test (double disc, individual disc with or without clavulanic
acid) and Hodge’s test (Table 1 and Figure 1). In contrast, no UPEC O25b strains producing
MBLs were identified with the three tests used.
A total of 47.61% (60/126) of the MDR and XDR UPEC O25b strains were positive for
class 1 integrons (Table 1), and only 38.33% (23/60) amplified a DNA amplicon of 1800 bp
of the variable region. Only 3.17% (4/126) of the MDR and XDR UPEC O25 strains were
positive for class 2 integrons, but only two strains amplified a DNA amplicon of 2000 bp of
the variable region (Table 1).
3.4. Virulence Gene and Phylogenetic Group Associations of UPEC O25b Clinical Strains
MDR and XDR UPEC O25b strains were primarily associated with two subgroups
belonging to phylogenetic group B2: 60.31% (76/126) were distributed to subgroup B22
and 9.52% (12/126) were distributed to subgroup B21 (Figure 1). For phylogenetic group D,
14.28% (18/126) were distributed in subgroup D1, and 11.11% (14/126) were distributed in
subgroup D2 (Figure 1). A total of 4.76% (6/126) of the MDR and XDR UPEC O25b strains
were grouped into phylogenetic subgroup A1 (Figure 1).
On the other hand, 95.23% (120/126) of the UPEC O25b strains carried the fimH gene,
91.26% (115/126) carried the csgA gene, 100% (126/126) carried the ecpA gene, and 10.31%
(13/126) carried the bcsA gene. The papGII gene of PapG fimbrial adhesin was the most
prevalent variant, and it was found in 80.95% (102/126) of the strains, followed by the
papGIII gene, which was found in 2.38% (3/126). Moreover, 99.20% (125/126) carried
the motA gene, and 99.20% (125/126) carried the motB gene. Both of these genes encode
flagellar motor proteins. In contrast, 31.74% (40/126) carried the fliC gene, which encodes a
structural protein of the flagellar filament. Other genes were also identified using multiplex
PCR: 95.23% (120/126) carried the chuA gene (coding for heme-binding proteins); 88.09%
(111/126) carried the iutD gene (coding for aerobactin); and 34.92% (44/126) carried the
fyuA gene (coding for yersiniabactin) (Figure 1). Genes encoding toxins were distributed
as follows: 84.92% (107/126) carried the satA gene (coding for a secreted autotransporter
toxin); 40.47% (51/126) carried the hlyA gene (coding for α-hemolysin); 13.49% (17/126)
carried the tosA gene (coding for the TosA protein); and 33.33% (42/126) carried the cnf1
gene (coding for the cytotoxic necrotizing factor) (Figure 1).
3.5. PFGE Genetic Diversity of UPEC O25b Strains
Dendrogram analysis generated with NTSYSpc and PAST v4.0 and edited with the
iTOL Interactive Tree of Life showed high genetic diversity, with 37% similarity among all
UPEC O25b strains (Figure 2). In summary, 124 different pulsotypes were identified among
the 126 strains with macrorestriction profiles of 11 to 24 bands. According to the analysis
of the phylogenetic groups and virulence factors of the MDR and XDR UPEC O25b strains,
31.74% (40/126) of these strains showed a similarity of ≥80%, which indicates a highly
related profile (Figure 2).
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Figure 2. Genetic diversity determined by PFGE of the UPEC O25b clinical strains. The diversity
analysis showed a cophenetic correlation coefficient value of r = 0.7917. ST: sequence type, M3:
resistance to three antibiotic categories, M4: resistance to four antibiotic categories, M5: resistance to
five antibiotic categories, M6: resistance to six antibiotic categories, M7: resistance to seven antibiotic
categories, X8: resistance to eight antibiotic categories, and X9: resistance to nine antibiotic categories.
3.6. STs and CCs Maintain an Association with UPEC O25b Clinical Strains
From analyses of STs and CCs, we selected 55 clinical strains of UPEC O5b based on
their resistance profiles, virulence, and clonality. Analysis of the STs revealed that 25.45%
(14/55) of the UPEC O25b strains belonging to phylogenetic group B2, with an MDR or XDR
profile, showed ST131. Furthermore, 21.81% (12/55) of UPEC O25b strains belonging to
phylogenetic group D were associated with ST69, which was the most prevalent. However,
UPEC O25b/ST131 strains were distributed among the five phylogenetic subgroups B21,
B22, D1, D2, and A1. The MLST analysis of the UPEC O25b strains identified the following
STs: ST73, ST405, ST93, ST394, ST10, ST120, ST62, ST117, ST443, ST998, ST421, and ST1177
(Table S2).
UPEC O25b strains grouped in phylogenetic group B2 were distributed primarily in
CC131, and strains grouped in phylogenetic group D were distributed in CC69. The UPEC
O25b MDR and XDR strains were distributed primarily in CC73, CC405, CC168, CC10,
CC205, CC95, CC394, and CC38 (Figure 3 and Table S2). The phylogenetic analysis of the
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CCs by eBURST showed a great dispersion of the CCs associated with UPEC O25b strains
(Figure 3).
Figure 3. eBURST analysis of UPEC O25b clinical strains. eBURST analysis was performed based
on single-locus variants (SLVs). Red shows the founding STs of a clonal complex (CC), and orange
shows the STs that differ in only one gene sequence from the founding group.
4. Discussion
UPEC O25b/ST131 strains are associated with community-acquired and nosocomial
UTIs in Mexico. These strains have a high resistance profile to several antibiotics that are
commonly used in UTI treatment and a wide repertoire of virulence genes that contribute
to UTI pathogenesis [28,29]. UPEC O25b/ST131 strains were successfully identified using
the amplified pabB gene [29–32]. Duplex PCR identification of the pabB and trpA genes
facilitated the selection of MDR and XDR UPEC clinical strains of serogroup O25b in
this work.
The present study identified 20.25% (126/622) of the UPEC strains from pediatric
patients with cUTIs as belonging to serogroup O25. Community-acquired (22.8%) and
hospital-acquired (55.6%) UTIs were associated with UPEC O25b/ST131 strains in Istanbul,
Turkey [33]. Ten percent of MDR strains were found to belong to the E. coli O25b/ST131
clonal group in Kuwait and represent a major public health risk [30]. A total of 44.23% of
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UPEC O25b/ST131 strains were associated with extraintestinal infections in Egypt [32].
UPEC O25b/ST131 strain producers of ESBLs from UTI pediatric patients have continu-
ously and significantly increased in prevalence in Taiwan, from 33% (2009) to 43% (2010),
74% (2011), and 68% (2012) [34]. Twenty-five percent of UPEC O25b/ST131 strains were as-
sociated with the ESBL phenotype in Mexico [28]. However, few reports have characterized
large populations of UPEC O25 strains in pediatric patients in Mexico. The carbapenemase-
producing O25b/ST131 clone was previously related to health-care-associated infections in
the Mexican pediatric population [35].
Among the UPEC strains classified as O25b from children, 81.74% were MDR and
18.25% were XDR. The multidrug resistance exhibited by E. coli O25b/ST131 strains in
extraintestinal infections was primarily associated with ESBL production of the CTX-M
type and fluoroquinolone resistance [28,36]. Our data showed high rates of resistance to
different antibiotic categories, including penicillins (99.20%); β-lactams combined with β-
lactamase inhibitors (92.85%); first-, second-, and third-generation cephalosporins (85.71%);
fluoroquinolones (77.77%); and ESBL phenotypic expression (64.28%). Similarly high
rates of resistance and ESBL production were described in other studies [28,30,33,36,37].
In contrast, UPEC O25b strains were most susceptible to carbapenem antibiotics, MEM
(7.94%), IPM (7.94%), and F/M (7.94%). Carbapenem and nitrofuran antibiotics are com-
monly used in the treatment of cUTIs, afebrile UTIs, and UTIs caused by ESBL-producing
strains [33,38,39]. However, the guidelines for UTI treatment must be constantly revised
for better antibiotic selection during routine use in children, and adequate epidemiological
surveillance must be performed [40,41].
Three UPEC O25b strains (532U-O25b, 289U-O25b, and 608U-O25b) were resistant
to one or two antibiotics, and these strains were associated with phylogenetic groups B2
and D1. Antibiotic susceptibility was primarily associated with resistance to AM and CF
(first generation), CEC (second generation), and CTX (third generation) cephalosporins.
However, the phenotypes of ESBL production and integron presence (classes 1 and 2) were
not identified. These two mechanisms of resistance spread significantly contributed to
the presence of MDR UPEC strains in Mexico [15,16]. UPEC strains were characterized
via the identification of several adhesion genes (fimH, csgA, papGII or papGIII, and ecpA),
siderophore and iron scavenger genes (iutD, fyuA, and chuA), flagellar genes (motA, motB,
and fliC), and toxin-coding genes (satA). Our data suggest that these sensitive UPEC
strains harbor several pathogenetic attributes that can produce cUTIs in pediatric patients
at HIMFG. These strains may be of commensal origin and have a high permissibility
of resistance gene acquisition via horizontal gene transfer. Additional whole-genome
sequencing studies are needed to verify whether these strains belong to ST131, a highly
disseminated clone worldwide. Healthy child carriers of commensal O25b/ST131 strains
are widely described, which indicates the relevant dissemination of this clonal lineage
worldwide [42,43].
UPEC O25b clinical strains were related to phylogenetic groups B21-2 (69.84%) and
D1-2 (25.39%) in the present study, which indicates their clinical origin. Phylogenetic group
B2 is related to the O25b-B2-ST131 clonal lineage in children and adults. A high percentage
of resistance to fluoroquinolones (77.77%), ESBL production (64.28%), and virulence genes
were detected in our study, which is similar to previously reported results [30,33,44]. MDR
UPEC clinical strains belonging to phylogenetic group D with high virulence potential
were identified in Mexican children with cUTIs [15,16]. Phylogenetic group D is related to
resistance transmission in E. coli strains of the urinary tract and intestinal origin in children
and adolescents [45]. Nonpathogenic E. coli strains associated with phylogenetic group
A are the most prevalent in the human intestinal microbiota, exhibit MDR profiles, are
closely correlated with cUTIs, and belong to O25b/ST131 [15,44,46]. In contrast, several
non-O25b/ST131 urinary tract E. coli strains belonging to phylogenetic groups D, A, and
BI are resistant to AMC, CTX, CAZ, cefoxitin, ticarcillin–clavulanic acid, and OFX and
carry the cefotaximase CTX-M-15 [47]. These data suggest that the O25b/ST131 clones
belonging to phylogenetic groups D and A represent the characteristic acquisition of
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virulence and resistance, which likely occurred during circulation in the patient’s colonic
microbiota, where there is strong selective pressure. Whole-genome sequencing studies
must be implemented to understand the relationship of these phylogenetic groups in
Mexican pediatric strains.
The genes encoding fimbrial adhesins, such as papGII, csgA, fimH, and ecpA, were
identified in 80 to 100% of the UPEC O25b/ST131 strains. This result was expected because
fimbrial adhesins promote bacterial adherence to the uroepithelium. The FimH and CsgA
adhesins participate in the process of bladder epithelium invasion and favor bacterial per-
sistence [16]. Virulence gene diversity is associated with isolation type, phylogenetic group,
serotype (O:H), and ST, but the main approach indicates that phylogenetic group B2 strains
are highly virulent [44]. UPEC O25b/ST131 clinical strains from the HIMFG harbored
>70% carrying chuA, >70% carrying iutD, and >30% carrying fyuA. The gene coding for
yersiniabactin is widely distributed in extraintestinal E. coli strains of several serotypes and
STs [44]. The hlyA toxin gene was more prevalent in extraintestinal E. coli strains in Spain
and France [44], but the satA gene was primarily identified in pediatric strains in Mexico.
Notably, the genes encoding flagellar motor proteins showed high frequency, i.e., 99.20%
for the motA and motB genes, but the fliC gene showed a low distribution (31.74%). Most
strains of UPEC O25b/ST131 were motile. However, no correlation was observed between
the low frequency of the fliC gene and the high percentages of motile UPEC strains, which
may be due to the high variability of the fliC gene. Flagellar mobility is a necessary factor
for urothelium colonization, and it favors bacterial ascent to the renal epithelium together
with P fimbria [48]. The expression of flagellar and fimbrial proteins may be inversely
coordinated, i.e., highly adherent strains may be nonmotile, and strains with low adherence
may be motile [49].
The TosA protein is a nonfimbrial adhesin that mediates adherence to the urinary
epithelium, and it is a virulence marker in UPEC strains [49,50]. MDR UPEC strain carriage
of the tosA gene maintains a high correlation with virulence gene presence [50,51]. Our
data showed a low frequency (13.74%) of the tosA gene in UPEC O25b-ST131 MDR and
XDR strains. The expression of several highly specialized fimbriae (type 1 fimbria, curli,
and P fimbria) is required for bacterial adherence to the uroepithelium and renal cells
via an on/off system, but the role of TosA in the colonization of the bladder and kidney
requires additional study.
High genetic diversity was found among the 126 UPEC O25b/ST131 MDR and XDR
strains. These data suggest that the origin of the clinical strains is related to large intestine
colonization with commensal strains of E. coli O25b/ST131, which enter the bladder due to
cross contamination and cause an ascending UTI. ESBL producer O25b/ST131 strains are
related to human, animal, and environmental health and food reservoirs [43,52–55]. Other
studies showed UTI-associated strains from the colonic microbiota of the same patient [45].
Regardless of the diversity in O25b/ST131 strains, some PFGE patterns may be more
common depending on the geographic area [30]. Our study found that 31.74% of strains
showed ≥ 80% similarity, which indicated that 40 of the 126 strains were highly related in
the pediatric population in the absence of direct patient contact. The commensal microbiota
is an important reservoir of resistance and virulence genes, which may be easily transferred
to pathogenic bacteria. Therefore, we hypothesize that commensal E. coli strains acquire
the necessary resistance and virulence factors to become uropathogens and increase the
possibility of acquiring a clinical infection.
UPEC O25b clinical strains were distributed in 14 STs; 22 of the strains were ST131
(25.45%) and related to phylogenetic group B2. The great diversity of STs between extrain-
testinal strains of E. coli is related to geographic region, population type, and temporality.
Some STs remain constant in a population over time, but others are highly mobile [56].
ST73, ST93, ST120, ST405, and ST998 were also identified as O25b strains of pediatric
origin. Phylogenetic group D with ST131 and A1 with ST131 were identified among
the UPEC strains with an MDR phenotype and a high virulence profile. These results
indicate that ST131 UPEC strains may spread to other populations with less frequent
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phylogenetic groups, which is of great importance in Mexico [16]. Most of the O25b
strains of phylogenetic group D belonged to ST69 and CC69 in our study, which have
spread worldwide and were identified in significant quantities among intestinal commensal
E. coli strains [57]. The ST69 clone is associated with fecal colonization in children and
adolescents, and it frequently exhibits an MDR profile due to a large conjugative plasmid,
which confers resistance to tetracycline and trimethoprim–sulfamethoxazole [45]. Among
all of the phylogenetic groups identified among the UPEC O25b strains, phylogenetic
group D showed a greater diversity of STs (ST10, ST62, ST73, ST405, ST443, ST117, ST421,
ST443, ST998, and ST1177). The ST distribution identified in our study is consistent with a
meta-analysis study that identified 20 STs as the most prevalent extraintestinal pathogenic
E. coli (ExPEC) strains worldwide, including ST131, ST69, ST10, ST405, ST38, ST95, ST73,
and ST1117 [56], and these STs were among the UPEC O25b strains from Mexican children.
The search continues for new agents with antibacterial activity, such as essential
oils extracted from plants with biological and pharmacological properties [58–61]. The
bioactivity of these oils may make them a viable therapy to reduce the current increase
in multidrug resistance in UPEC clinical strains, including the O25b/ST131 serogroup,
which represents a serious health problem and a great challenge for public health around
the world.
5. Conclusions
UPEC O25b strains from Mexican children in the HIMFG had high resistance to seven
antibiotic categories characterized by ESBL expression and class 1 integron carriage. The
UPEC O25b strains also harbored several virulence genes involved in adherence, motility,
toxicity, and iron uptake. The resistance and virulence of the UPEC O25b strains were
related to phylogenetic groups B22 and D1. High genetic diversity was related to 14 STs
and 10 CCs of worldwide importance and distribution, which suggests a commensal origin
of the O25b strains. The various pathogenic attributes identified in UPEC O25b strains,
including resistance, significantly complicate and reduce the choice of antibiotics for the
treatment of UTIs. These studies contribute to the implementation of strategies for the
control of MDR UPEC strains associated with UTIs.
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